<DOC>
	<DOCNO>NCT00714753</DOCNO>
	<brief_summary>RATIONALE : Internal radiation use radioactive material place directly near tumor kill tumor cell . Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . PURPOSE : This phase II trial study side effect internal radiation therapy give without external-beam radiation therapy see well work treat patient localized prostate cancer .</brief_summary>
	<brief_title>Internal Radiation Therapy With Without External-Beam Radiation Therapy Treating Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate tolerability 2 radiotherapeutic regimen ( high dose-rate brachytherapy [ HDR ] without image-guided intensity-modulated hypofractionated external beam radiotherapy [ EBRT ] ) , measure Common Terminology Criteria Adverse Events ( CTCAE v3.0 ) , patient localized prostate cancer . Secondary - Identify association dose-volume parameter organ risk rate severity genitourinary gastrointestinal adverse event . - Evaluate patient preference regard selection second treatment ( second HDR brachytherapy session EBRT session ) . - Evaluate patient-reported health-related quality life ( HRQOL ) measure validated HRQOL instrument 5 year . - Describe probability freedom biochemical clinical failure . - Describe probability freedom salvage androgen suppression . OUTLINE : Patients undergo high dose-rate ( HDR ) brachytherapy ( 2 fraction ≥ 5 hour apart ) . Beginning 2-4 week completion first HDR brachytherapy session , patient undergo either second session HDR brachytherapy ( 2 fraction ≥ 5 hour apart ) OR image-guided intensity-modulated hypofractionated external beam radiotherapy daily 5 day week 3 week . Quality life assess baseline , prior second treatment session , 1 6 month completion treatment , every 6 month 3 year , annually 2 year . After completion study treatment , patient follow 1 6 month , every 6 month 3 year , annually 2 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate , meet one follow criterion : Lowrisk disease ( T1T2a , Gleason score ≤ 6 , PSA &lt; 10 ng/mL ) Low intermediaterisk disease ( T1T2c , Gleason score ≤ 6 , PSA &lt; 20 ng/mL OR T1T2a , Gleason score 7 , PSA &lt; 10 ng/mL ) No know nodal ( N0 NX ) distant ( M0 MX ) metastases No pubic arch interference , define either follow : Maximum transrectal ultrasounddetermined anteriorposterior ( zaxis ) dimension &lt; 4.3 cm No 25 % prostate volume block ( pubic arch ) CT scan simulation A10°I beam 's eye view Prostate planimetry volume ≤ 60 cc determine stepsection transrectal ultrasound American Urological Association void symptom index ≤ 12 Peak uroflow rate ( Q_max ) ≥ 12 cc/second Postvoid ultrasound bladder residual volume ≤ 100 cc PATIENT CHARACTERISTICS : Zubrod performance status 01 Life expectancy ≥ 5 year WBC &gt; 2,000/μL Platelet count &gt; 100,000/μL PT &lt; 1.5 time upper limit normal No diabetes mellitus associate vascular ulcer woundhealing problem No blood dyscrasias No inflammatory bowel disease No connective tissue disorder No prior concurrent invasive malignancy ( except nonmelanoma skin cancer ) lymphomatous hematological malignancy ( except chronic lymphocytic leukemia/lymphoma ) unless patient continually diseasefree ≥ 5 year No medical psychiatric condition would preclude give informed consent comply study treatment Able undergo anesthesia PRIOR CONCURRENT THERAPY : No prior transurethral resection prostate No prior prostatic cryoablation highintensity focus ultrasound No prior prostatectomy No prior prostatic enucleation No prior pelvic external beam radiotherapy No prior radionuclide prostate brachytherapy No prior hemi total hip arthroplasty Neoadjuvant androgen suppression therapy allow provide initiated 26 month prior study entry total duration ≤ 6 month No concurrent anticoagulation therapy , include heparin coumadin</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>